A COMPARATIVE STUDY OF MYO INOSITOL VERSUS METFORMIN ON BIOCHEMICAL PROFILE IN POLYCYSTIC OVARIAN SYNDROME IN WOMEN
AbstractObjective: PCOS is a common endocrine disorder in women of reproductive age associated with insulin resistance. Metformin and Myo-inositol being insulin sensitizers improve biochemical parameters. This study was done to compare the effects of these drugs on biochemical profile in PCOS. Material and Methods: A prospective, open labeled, randomized, comparative, clinical study was conducted on 60 patients. The patients were randomly divided in two groups of 30 each to receive either of the following two treatments: Group A: Tab Myo-inositol 1g twice daily & Group B: Tab Metformin 500 mg thrice daily for 24 weeks. Biochemical profile was assessed by measuring fasting blood sugar, insulin levels & calculating glucose/insulin ratio and homeostatic model assessment- insulin resistance (HOMA-IR) index at baseline and subsequently at the end of 12 & 24 weeks. Serum Lipid profile was also assessed. Results: In both the groups, there was statistically significant improvement in insulin resistance. In group A & group B, the values for glucose/ insulin ratio improved from 6.77±0.99 to 7.87±1.03 and 5.5±0.42 to 6.90±0.47 respectively at the end of 24 weeks. HOMA-IR values decreased from 4.18±0.4 to 2.88±0.27 & 4.38±0.43 to 2.99±0.29 in group A & B respectively over a period of 24 weeks. Lipid profile was also improved in both the groups. However, on comparing both the groups, no statistically significant difference was observed. Conclusion: There was a definite improvement in biochemical profile with both metformin and myo-inositol. Thus, myo-inositol can be a new addition in the armamentarium for the treatment of PCOS.
Article Information
19
1664-1670
464
2238
English
IJPSR
J. Nehra *, J. Kaushal, S. Rani Singhal and V. Singh Ghalaut
Department of Pharmacology, Pt. B. D. Sharma PGIMS, Rohtak, Haryana, India.
jyotinhr7@gmail.com
13 September, 2016
26 November, 2016
28 November, 2016
10.13040/IJPSR.0975-8232.8(4).1664-70
01 April, 2017